Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab

被引：2
|
作者：
Hiraga, Junji [1 ]
Tomita, Akihiro [2 ]
Suzuki, Naruko [1 ]
Takagi, Yusuke [1 ]
Narita, Michihiko [3 ]
Kagami, Yoshitoyo [1 ]
机构：
[1] Toyota Kosei Hosp, Dept Hematol, 500-1 Ibobara,Josui Cho, Toyota 4700396, Japan
[2] Fujita Hlth Univ, Sch Med, Dept Hematol, Toyoake, Aichi, Japan
[3] Toyota Kosei Hosp, Dept Pathol, Toyota, Japan
来源：
ANNALS OF HEMATOLOGY | 2018年 / 97卷 / 11期
关键词：
CHEMOTHERAPY PLUS RITUXIMAB; CHOP;
D O I：
10.1007/s00277-018-3354-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2253 / 2255
页数：3
相关论文
共 50 条
  • [31] Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: A case report
    Rahme, Ramy
    Benayoun, Emmanuel
    Pautas, Cecile
    Cordonnier, Catherine
    Wagner-Ballon, Orianne
    Maury, Sebastien
    EXPERIMENTAL HEMATOLOGY, 2013, 41 (06) : 505 - 507
  • [32] Diffuse large B-cell lymphoma, leg type with loss of CD20 expression
    Thomas, A.
    Cibull, T.
    O'Malley, D.
    Billings, S.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2007, 34 (01) : 116 - 116
  • [33] Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy
    Maeshima, Akiko Miyagi
    Taniguchi, Hirokazu
    Fujino, Takahiro
    Saito, Yo
    Ito, Yuta
    Hatta, Shunsuke
    Yuda, Sayako
    Makita, Shinichi
    Fukuhara, Suguru
    Munakata, Wataru
    Suzuki, Tatsuya
    Maruyama, Dai
    Izutsu, Koji
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2141 - 2148
  • [34] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
    Seliem, RM
    Freeman, JK
    Hasserjian, RP
    BLOOD, 2002, 100 (11) : 311B - 311B
  • [35] Extranodal primary CD20-negative diffuse large B-cell lymphoma with cytoplasmic p16 expression
    Van Hung, Nguyen
    Huong, Nguyen Thuy
    Thanh, Nguyen Tuan
    Minh, Tran Ngoc
    Luan, Dao Thi
    BIOMEDICAL RESEARCH AND THERAPY, 2022, 9 (06): : 5089 - 5094
  • [36] Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma
    Matsuda, Ikuo
    Hirota, Seiichi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (08): : 9737 - 9741
  • [37] CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma-Analyses of the Molecular Mechanisms and Rituximab Effectiveness
    Tokunaga, Takashi
    Tomita, Akihiro
    Hiraga, Junji
    Sugimoto, Takumi
    Shimada, Kazuyuki
    Sugimoto, Keiki
    Kinoshita, Tomohiro
    Naoe, Tomoki
    BLOOD, 2011, 118 (21) : 1142 - 1143
  • [38] C-terminal deletion mutation of CD20 is related to low CD20 expression and shortened time to progression after rituximab treatment in non-Hodgkin's lymphoma
    Terui, Yasuhito
    Mishima, Yuji
    Hatake, Kiyohiko
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3396S - 3396S
  • [39] CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20(+), surface CD20(-)
    Yokose, Norio
    Shioi, Yumiko
    Sugisaki, Yuich
    Ohaki, Yoshiharu
    Ogata, Kiyoyuki
    Dan, Kazuo
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1415 - 1417
  • [40] Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy
    Akiko Miyagi Maeshima
    Hirokazu Taniguchi
    Takahiro Fujino
    Yo Saito
    Yuta Ito
    Shunsuke Hatta
    Sayako Yuda
    Shinichi Makita
    Suguru Fukuhara
    Wataru Munakata
    Tatsuya Suzuki
    Dai Maruyama
    Koji Izutsu
    Annals of Hematology, 2020, 99 : 2141 - 2148
12345